Seaside Therapeutics Reports Positive Data from Phase 2 Study of STX209 in Autism Spectrum Disorders

Source: 
Seaside Therapeutics
Date Published: 
September 9, 2010
Abstract: 

Seaside Therapeutics reported findings on STX209 at the 42nd Autism Society National Conference. STX209 is a selective gamma-amino butyric acid type B (GABA-B) receptor agonist being studied for the treatment of ASD and fragile X syndrome (FXS).

As previously reported, STX209 demonstrated statistically significant improvements across a number of global and specific neurobehavioral outcomes in the open-label Phase 2a study, including significant improvements in social impairment—a core symptom of ASD.